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Abstract
Background: The Wnt signaling pathway is abnormally activated in many human cancers. Secreted frizzled-related
proteins (SFRPs) function as negative regulators of Wnt signaling and play an important role in carcinogenesis. SFRP
promoter hypermethylation has often been identified in human cancers; however, the precise role of SFRPs in
cutaneous squamous cell carcinoma (SCC) is unclear.
Methods: The methylation status of the SFRP family was analyzed in an age-and sex-matched case-control study,
including 40 cutaneous SCC cases and 40 normal controls, using the MassARRAY EpiTYPER system.
Results: The methylation rate of SFRP1, SFRP2, SFRP4, and SFRP5 promoters was significantly higher in cutaneous
SCC tissues than in adjacent tissue and normal skin samples.
Discussion: Our manuscript mainly discussed the average methylation rate of SFRPs (SFRP1, SFRP2, SFRP4, and
SFRP5) promoters are significantly high in tumor tissue samples and the average CpG island methylation rate
among different pathological levels of cutaneous SCC between these genes are different.
Conclusions: Our findings suggest that promoter hypermethylation of SFRPs is associated with the development of
carcinoma, and could be a useful tumor marker for cutaneous SCC and other types of cancers.
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Background
Non-melanoma skin carcinomas, comprising cutaneous
squamous cell carcinoma (SCC) and basal cell carcinoma
(BCC), are the most common malignancies in fair-skinned
Caucasians [1]. Unlike almost all basal cell carcinomas,
cutaneous SCCs are associated with a substantial risk of
metastasis [2]. The etiology of cutaneous SCC is multifac-
torial, with both environmental and host factors being im-
portant. However, exposure to ultraviolet radiation is the
most common cause [3, 4]. Other risk factors include im-
paired immune surveillance, as seen in organ transplant
recipients, and human papillomavirus infections [5].
The Wnt family of proteins includes a wide range of
secreted growth factors that regulate cell differentiation,
proliferation, migration, and organogenesis during em-
bryonic development [6]. Aberrant activation of the Wnt
pathway has been observed to inhibit tumor cell apop-
tosis during human carcinogenesis [7, 8]. Wnt signaling
is activated on binding of the Wnt ligand to the frizzled
membrane receptor [9], and a family of five secreted
frizzled-related glycoproteins (SFRP1-5) has been identi-
fied as modulators of Wnt signaling [10]. Moreover, the
epigenetic silencing of SFRP genes, leading to oncogenic
activation of the Wnt pathway and tumor progression
was reported in many human cancers [11–14].
Although the involvement of Wnt signaling in carcino-
genesis has been extensively studied, the associations of
the SFRP family with tumorigenesis have only recently
begun to be explored. Previous studies have reported
SFRP downregulation in colorectal cancer, gastric cancer
[15], and invasive breast tumors [16, 17]. Additionally,
Wnt5a signaling was found to contribute to tissue inva-
sion by non-melanoma skin cancer, including both SCC
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and BCC [18]. Although non-melanoma skin cancer is
common, the incidence in China is very low, and differ-
ences have been demonstrated between Caucasians and
Hong Kong Chinese patients regarding disease features
[19]. In the present study, we used the Mass ARRAY
EpiTYPER system to examine the methylation status of
SFRP family members, including SFRP1, SFRP2, SFRP4,
and SFRP5 in different tissue samples from a Chinese
population of the Xinjiang Uygur Autonomous Region.
Methods
Study populations and tissue samples
To investigate the methylation status of the SFRP family,
we conducted an age- and gender- matched case-control
study including 40 cutaneous SCC cases and 40 normal
controls. The patients were recruited from the Dermatol-
ogy Department of the People’s Hospital of Xinjiang Uygur
Autonomous Region (Xinjiang, China), and had received a
diagnosis of histologically confirmed cutaneous SCC be-
tween January 2012 and February 2014. Controls were nor-
mal individuals from the Plastic Surgery Department of the
hospital who reported no history of any type of cancer at
the time of study recruitment. The basic characteristics for
the participants included in this study are presented in
Table 1. Cutaneous SCC tissues (n = 40) and adjacent tis-
sues (n = 40) were obtained from the head or the hands/
legs of the 40 cutaneous SCC patients. Normal skin sam-
ples (n = 40) were collected from the face or the hands/legs
of the 40 controls. This study was approved by the ethics
committee of the People’s Hospital of Xinjiang Uygur Au-
tonomous Region. Written informed consent was also ob-
tained from each participant enrolled in the study.
DNA extraction, sodium bisulfite modification, and PCR
Genomic DNA from tissue samples was extracted using
the Tissue DNA Kit (Qiagen) according to the manufac-
turer’s recommendations. The DNA concentration and
quality were measured using the NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Houston,
TX). Bisulfite modification of genomic DNA was per-
formed using the EZ DNA Methylation Kit (Zymo
Research) according to the manufacturer’s protocol.
Bisulfite-treated genomic DNA was amplified in a 384-
well plate using HotStar Taq Polymerase in a 5-μl reaction
volume (Qiagen). PCR conditions were 94 °C for 4 min
followed by 45 cycles of 95 °C for 20 s, 56 °C for 20 s, and
72 °C for 60 s, with a final extension of 72 °C for 3 min.
Primer sequences are given in Table 2.
Quantitative DNA methylation analysis by MassARRAY
EpiTyper
The PCR products were treated according to the standard
protocol (Sequenom EpiTyper Assay) by SAP treatment
and T-cleavage reaction. The samples were then cleaned
by Resin and were dispensed to a 384 SpectroCHIP by
Nanodispenser. DNA methylation levels were determined
as previously described [20] using MassARRAY EpiTYPER
(SEQUENOM Inc., Herston, QLD, Australia) system,
which is based on MALDI-TOF MS [21]. The mass
spectrum was collected by MassARRAY Spectrometer
and analyzed by EpiTYPER v.1.0 software (SEQUENOM).
Statistical analysis
The SPSS 17.0 statistical software (SPSS Inc., Chicago, IL,
USA) and Microsoft Excel (Microsoft Corporation, Red-
mond, WA, USA) were used for statistical analysis. The
methylation levels in cutaneous SCC patients and normal
samples were compared by nonparametric Mann-Whitney
U test or the Kruskal-Wallis H test. All P-values presented
in this study were two sided, and we used P < 0.05 as the
cutoff value for statistical significance. The receiver operat-
ing characteristic (ROC) curve was used to estimate the
specificity, sensitivity, and accuracy of the regression test.
Results
In the present study, we investigated the methylation
status of SFRP1, SFRP2, SFRP4, and SFRP5 in 40 cutane-
ous SCC patients and 40 normal subjects. Table 1
showed the distribution of age, sex, and pathological
level among cases and controls. The mean age for the
case group was 67.11 ± 9.24 years and 64.31 ± 8.91 years
for the control group. There were no significant differ-
ences in age and sex distribution between the case and
control groups (p > 0.05).
We investigated the promoter methylation rate of
SFRP1, SFRP2, SFRP4, and SFRP5 in 40 cutaneous SCC
tissues, 40 adjacent tissues, and 40 normal samples using
the MassARRAY EpiTYPER system. Aberrant promoter
methylation of SFRP1, SFRP2, SFRP4, and SFRP5 was de-
tected in cutaneous SCC tissues and adjacent tissues com-
pared with normal samples. Additionally, the frequency of
Table 1 Basic characteristics of the cases and controls in this
study
Variables Case (N = 40) Control (N = 40) Total p-value
Sex, No. (%) 0.749*
Male 21 (52.50) 22 (55.00) 43
Female 19 (47.50) 18 (45.00) 37
40 40
Grade, No. (%)
Stage I 21 (52.50)
Stage II 12 (30.00)
Stage III 7 (17.50)
Stage IV 0
Mean age ± SD 67.11 ± 9.24 64.31 ± 8.91 0.707**
*P values were calculated from two-sided chi-squared tests
**P values were calculated by Student’s t-tests
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Table 2 Primer sequences for amplifying SFRP genes
Gene Forward Reverse bp CpGs Tm
SFRP1 SFRP1_1 aggaagagagTATGTGTGTTTGAGTGATGGATTTG cagtaatacgactcactatagggagaaggctAAACAACACCTCTCCAAATAAAACC 290 7 56
SFRP1_2 aggaagagagAGTTTGGGAGGTTAAGGTAGGAGTA cagtaatacgactcactatagggagaaggctAAAACCTAAATCATACTTACAAACCCAT 300 12 56
SFRP2 SFRP2_1 aggaagagagGGTTAGGTTTTTTTGTTTGTTGTTT cagtaatacgactcactatagggagaaggctCACAACCAAAATTTTCTTAACCTTT 235 9 56
SFRP2_2 aggaagagagGGGGATGAATGAGTTAATTTTAGTT cagtaatacgactcactatagggagaaggctAAAAATCTCACCAATCACACAAAAC 296 9 56
SFRP4 SFRP4_1 aggaagagagGTATGTGTGTTTGAGTGATGGATTT cagtaatacgactcactatagggagaaggctTCCCAACTAACAAAAATTCAAAAAA 314 6 56
SFRP4_2 aggaagagagTTTTGAATTTTTGTTAGTTGGGAAA cagtaatacgactcactatagggagaaggctAAAACCTAAATCATACTTACAAACCCA 390 36 56
SFRP5 SFRP5_1 aggaagagagGTATGTGTGTTTGAGTGATGGATTT cagtaatacgactcactatagggagaaggctTCCCAACTAACAAAAATTCAAAAAA 323 6 56
SFRP5_2 aggaagagagTTTTGAATTTTTGTTAGTTGGGAAA cagtaatacgactcactatagggagaaggctAAAACCTAAATCATACTTACAAACCCA 329 6 56











SFRP promoter methylation in tumors was significantly
higher than in adjacent tissues and normal samples
(Table 3).
We also assessed the average CpG island methyla-
tion rate of SFRPs among different pathological levels
of cutaneous SCC. We observed a significant increase
in the methylation rate of different SFRP CpG islands
with higher pathological levels (Table 4). CpG island
methylation of different SFRPs was shown to vary
among different tissues. The methylation rate was also
much higher in cutaneous SCC tissues than in adja-
cent tissues, but was lower in normal control samples
(Fig. 1a–d).
Finally, we performed ROC curve analysis of SFRP1
CpG island methylation (Fig. 2). ROC curve is a graphic
presentation of the relationship between both sensitiv-
ity and specificity, and it helps to decide the optimal
model through determining the best threshold for a
diagnostic/predictive test [22]. The area under the curve
(AUC) of the ROC curves provides a way to measure the
accuracy of a diagnostic/predictive test. The larger the
area, the more accurate the test is [22]. As shown in Fig. 2,
all these six CpG sites showed high AUC of the ROC
curves, ranging from 0.725 to 0.903. These results indicate
that the detection of SFRP1 CpG methylation may be used
as an early biomarker for SCC diagnosis.
Discussion
Cutaneous SCC is the second most common cancer
among Caucasians [2]. Although it has been suggested
to arise through the accumulation of multiple genetic
changes involving a complex multi-step process [1], the
precise pathogenesis remains unclear. However, numer-
ous studies have recently shown that the epigenetic
dysregulation of tumor suppressor genes could serve as
a biomarker to predict the diagnosis and prognosis of
human disease and malignancy [23–25].
In the present study, we describe the aberrant DNA
methylation of four members of the SFRP family, SFRP1,
SFRP2, SFRP4, and SFRP5, in cutaneous SCC in a
Chinese population. Methylation of these genes has been
reported previously in lung cancer, prostate cancer, colo-
rectal cancer [26], and human glioblastoma [27]. Addition-
ally, several studies have reported the lack of methylation
in nonmalignant tissues and described methylation as a
tumor-restricted event [23, 28, 29]. Here, we showed that
frequent promoter hypermethylation of SFRPs was signifi-
cantly elevated in cutaneous SCC samples compared with
adjacent tissues and control samples. Interestingly, we also
observed marked differences in the levels of aberrant
DNA methylation between these genes (SFRP1, SFRP2,
SFRP4, and SFRP5), suggesting that hypermethylation of
these SFRPs, particularly of SFRP1, could be important in
the onset of cutaneous SCC.
Aberrant hypermethylation of CpG islands in gene
promoters was previously shown to be a primary mech-
anism in the inactivation of several tumor suppressor
genes [30]. We assessed the methylation status of the
CpG islands in SFRP promoters in different patho-
logical levels of cutaneous SCC tissue, and found the
methylation rate to increase with the pathological level.
ROC curve analysis showed that the SFRP1 CpG site is
a potential biomarker of cutaneous SCC, and the fur-
ther identification of genes that are methylated during
cutaneous SCC carcinogenesis together with an im-
provement in the quantitative rather than the qualita-
tive analysis of methylation will be of great value in the
future molecular screening of cutaneous SCC.
The potential importance of SFRP silencing in cutane-
ous SCC relates to its involvement in the Wnt signaling
pathway. This pathway is involved in the tumorigenesis
of many human cancers, including those of the colon,
breast, lung, and liver, as well as melanomas [7]. Chung
et al. also recently demonstrated the frequent aberrant
methylation of SFRPs in cervical SCC [31]. Additionally,
two further studies indicated that frequent aberrant
methylation of SFRPs occurs in hepatocellular carcin-
oma, and that restoration of SFRP1 attenuates Wnt
signaling, decreases the abnormal accumulation of β-
catenin in the nucleus, and suppresses cell growth
[32, 33]. To date, however, the regulation of the Wnt
pathway in cutaneous SCC has remained unclear. Pour-
reyron et al. [18] demonstrated that Wnt5a is overex-
pressed in non-melanoma skin cancer, which contributes
to tissue invasion. Additionally, the study presented here
also suggests the upregulation of SFRP1 and SFRP2 ex-
pression in cutaneous SCC, in particular SFRP2, exhibit
very high constitutive expression in normal skin. The data
provided by the Human Protein Atlas on cutaneous SCC
(www.proteinatlas.org) showing that the SFRPs (SFRP1,
SFRP2, SFRP4, and SFRP5) exhibit very low expression in
cancer tissues, except SFRP1, which was slightly high. Our
results showed that the SFRPs were highly methylated in
cutaneous SCC, which in accordance with the data of the
Table 3 Methylation frequency (%) comparison of SFRP CpG
sites in three tissue groups
Genes No. of CpG
islands
Frequency of promoter methylation (%)
T vs. N T vs. A A vs. N
SFRP1 17 82.35 (14/17) 58.82 (10/17) 29.41 (5/17)
SFRP2 14 50 (7/14) 57.14 (8/14) 42.86 (6/14)
SFRP4 18 72.22 (13/18) 72.22 (13/18) 61.11 (11/18)
SFRP5 11 54.54 (6/11) 54.54 (6/11) 54.54 (6/11)
P*-value <0.05 <0.05 <0.05
T tumor tissues; A adjacent tissues; N normal samples
*Nonparametric Mann-Whitney U test
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Human Protein Atlas on cutaneous SCC. Nevertheless,
much work remains to be done to obtain a clearer under-
standing of the role of SFRPs in Wnt signaling and tumor
pathogenesis.
Conclusions
In conclusion, our study demonstrates that promoter
hypermethylation of SFRPs (SFRP1, SFRP2, SFRP4, and
SFRP5) is associated with the development of cutane-
ous SCC. Although it is not possible to determine
whether SFRPs are directly related to carcinogenesis
from this study, the aberrant methylation of SFRPs may
nevertheless be a useful tumor biomarker for early
diagnosis. Despite the current study possessing enough
statistical power, some limitations should be consid-
ered. First, we limited our investigation to only four
SFRPs: SFRP1, SFRP2, SFRP4, and SFRP5. Therefore,
we cannot exclude the possibility that other genes may
play a role in the pathogenesis of cutaneous SCC. Sec-
ond, the sample size of our study was relatively small,
so our findings should be confirmed in larger case-
control studies.
Table 4 Methylation frequency (%) of SFRP CpG islands at different cutaneous SCC pathological levels
Gene CpG Site Stage I Stage II Stage III H P-value
N x  s N x  s N x  s
SFRP1 CpG1_5 0 0.4012 ± 0.098 0 0.4521 ± 0.115 9 0.4952 ± 0.109 6.157 0.024*
CpG1_7 9 0.4011 ± 0.134 6 0.4811 ± 0.024 2 0.5121 ± 0.124 5.103 0.031
CpG2_1 7 0.4141 ± 0.19 0 0.4267 ± 0.314 2 0.4013 ± 0.217 2.136 0.021
CpG2_8 5 0.4231 ± 0.824 7 0.4501 ± 0.224 4 0.5011 ± 0.523 8.514 0.017
SFRP2 CpG1_5 44 0.3329 ± 0.101 29 0.3796 ± 0.170 19 0.4241 ± 0.183 6.142 0.015
CpG2_1 47 0.4094 ± 0.036 48 0.4367 ± 0.316 17 0.4713 ± 0.107 6.136 0.023
CpG2_3.4 55 0.4017 ± 0.098 42 0.4406 ± 0.194 18 0.4891 ± 0.153 5.218 0.015
SFRP4 CpG1_3 2 0.3029 ± 0.089 3 0.3496 ± 0.012 2 0.3867 ± 0.083 7.158 0.009
CpG2_2 9 0.2994 ± 0.037 2 0.3367 ± 0.016 5 0.4113 ± 0.086 7.156 0.023
SFRP5 CpG1_5 40 0.3014 ± 0.052 33 0.3834 ± 0.021 18 0.4345 ± 0.037 5.54 0.031
CpG2_1 32 0.2941 ± 0.098 19 0.3167 ± 0.314 34 0.4013 ± 0.057 3.136 0.021
N: number of samples; H: the Kruskal-Wallis H test
*p ≤ 0.05 indicates statistical significance
Fig. 1 Comparison of average CpG island methylation rate in the SFRP gene family. T, tumor tissues; A, adjacent to carcinoma tissue; N, normal
tissue samples
Liang et al. BMC Cancer  (2015) 15:641 Page 5 of 7
Fig. 2 Receiver operating characteristic (ROC) curves for six CpG sites in the SFRP1 promoter. The ROC curves plot sensitivity and 1-specificity.
Areas under the curve (AUC) and P values were shown in the graph
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